Biogen Inc., a multinational biopharmaceutical company based in Cambridge, Massachusetts, has established itself as a leading player in the treatment of neurological and neurodegenerative diseases worldwide. With a presence across the United States, Europe, Germany, and Asia, Biogen boasts an impressive portfolio of therapies, including TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis, SPINRAZA for spinal muscular atrophy, ADUHELM for Alzheimer's disease, and FUMADERM for plaque psoriasis. The company is also behind biosimilars BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ, referencing ENBREL, HUMIRA, REMICADE, and LUCENTIS, respectively. The offerings extend further to include Rituxan, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, glofitamab, and others for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, vasculitis, pemphigus vulgaris, and other conditions. Meanwhile, Biogen continuously innovates with various products and projects under development, focusing on MS, Alzheimer's disease, neuromuscular disorders, Parkinson's disease, and biosimilars. The company has partnered with Acorda Therapeutics, Inc., Denali Therapeutics Inc., Eisai Co., Ltd., Genentech Inc., Samsung Bioepis Co., Ltd., Sage Therapeutics, Inc., among others, to advance research and development. Biogen was founded in 1978 and is at the forefront of the biotech industry.
Biogen's ticker is BIIB
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 5001-10,000 employees working at Biogen
It is biogen.com
Biogen is in the Healthcare sector
Biogen is in the Biotechnology industry
The following five companies are Biogen's industry peers: